Clinical Study to Evaluate the Pharmacokinetics and Safety of CKD-383 0.5/25/1000mg in Healthy Volunteers

NCT07304687 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

31

Enrollment

INDUSTRY

Sponsor class

Conditions

Type 2 Diabetes

Interventions

DRUG: CKD-383 0.5/25/1000mg
DRUG: CKD-501, D745, D150

Sponsor

Chong Kun Dang Pharmaceutical